Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 37 entries
Sorted by: Best Match Show Resources per page
Reply.

Gastroenterology

Omidvari AH, Lansdorp-Vogelaar I, Rubenstein JH.
PMID: 34597673
Gastroenterology. 2021 Sep 28; doi: 10.1053/j.gastro.2021.09.056. Epub 2021 Sep 28.

No abstract available.

Cite
Omidvari AH, Lansdorp-Vogelaar I, Rubenstein JH. Reply. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.09.056.
Omidvari, A. H., Lansdorp-Vogelaar, I., & Rubenstein, J. H. (2021). Reply. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.09.056
Omidvari, Amir-Houshang, et al. "Reply." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.09.056
Omidvari AH, Lansdorp-Vogelaar I, Rubenstein JH. Reply. Gastroenterology. 2021 Sep 28; doi: 10.1053/j.gastro.2021.09.056. Epub 2021 Sep 28. PMID: 34597673.
Copy Download .nbib Format: NLM
Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands.

European journal of cancer (Oxford, England : 1990)

Toes-Zoutendijk E, Vink G, Nagtegaal ID, Spaander MCW, Dekker E, van Leerdam ME, Siesling S, Lansdorp-Vogelaar I, Elferink MAG.
PMID: 34915408
Eur J Cancer. 2021 Nov 24;161:38-43. doi: 10.1016/j.ejca.2021.11.008. Epub 2021 Nov 24.

Many countries had to suspend their colorectal cancer (CRC) screening programme as a result of the COVID-19 pandemic. This eventually may lead to postponed diagnoses of premalignant lesions and CRC, resulting in increased incidence or more advanced CRCs rates....

Cite
Toes-Zoutendijk E, Vink G, Nagtegaal ID, et al. Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. Eur J Cancer. 2021;161:38-43doi: 10.1016/j.ejca.2021.11.008.
Toes-Zoutendijk, E., Vink, G., Nagtegaal, I. D., Spaander, M. C. W., Dekker, E., van Leerdam, M. E., Siesling, S., Lansdorp-Vogelaar, I., Elferink, M. A. G. (2021). Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. European journal of cancer (Oxford, England : 1990), 16138-43. https://doi.org/10.1016/j.ejca.2021.11.008
Toes-Zoutendijk, Esther, et al. "Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands." European journal of cancer (Oxford, England : 1990) vol. 161 (2021): 38-43. doi: https://doi.org/10.1016/j.ejca.2021.11.008
Toes-Zoutendijk E, Vink G, Nagtegaal ID, Spaander MCW, Dekker E, van Leerdam ME, Siesling S, Lansdorp-Vogelaar I, Elferink MAG. Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. Eur J Cancer. 2021 Nov 24;161:38-43. doi: 10.1016/j.ejca.2021.11.008. Epub 2021 Nov 24. PMID: 34915408.
Copy Download .nbib Format: NLM
Reply.

Gastroenterology

Omidvari AH, Lansdorp-Vogelaar I, Rubenstein JH.
PMID: 34597673
Gastroenterology. 2022 Jan;162(1):351-352. doi: 10.1053/j.gastro.2021.09.056. Epub 2021 Sep 28.

No abstract available.

Cite
Omidvari AH, Lansdorp-Vogelaar I, Rubenstein JH. Reply. Gastroenterology. 2021;162(1):351-352doi: 10.1053/j.gastro.2021.09.056.
Omidvari, A. H., Lansdorp-Vogelaar, I., & Rubenstein, J. H. (2022). Reply. Gastroenterology, 162(1), 351-352. https://doi.org/10.1053/j.gastro.2021.09.056
Omidvari, Amir-Houshang, et al. "Reply." Gastroenterology vol. 162,1 (2022): 351-352. doi: https://doi.org/10.1053/j.gastro.2021.09.056
Omidvari AH, Lansdorp-Vogelaar I, Rubenstein JH. Reply. Gastroenterology. 2022 Jan;162(1):351-352. doi: 10.1053/j.gastro.2021.09.056. Epub 2021 Sep 28. PMID: 34597673.
Copy Download .nbib Format: NLM
Correction: Effects of cancer screening restart strategies after COVID-19 disruption.

British journal of cancer

Kregting LM, Kaljouw S, de Jonge L, Jansen EEL, Peterse EFP, Heijnsdijk EAM, van Ravesteyn NT, Lansdorp-Vogelaar I, de Kok IMCM.
PMID: 33976368
Br J Cancer. 2021 Jul;125(1):145. doi: 10.1038/s41416-021-01427-5.

No abstract available.

Cite
Kregting LM, Kaljouw S, de Jonge L, et al. Correction: Effects of cancer screening restart strategies after COVID-19 disruption. Br J Cancer. 2021;125(1):145doi: 10.1038/s41416-021-01427-5.
Kregting, L. M., Kaljouw, S., de Jonge, L., Jansen, E. E. L., Peterse, E. F. P., Heijnsdijk, E. A. M., van Ravesteyn, N. T., Lansdorp-Vogelaar, I., & de Kok, I. M. C. M. (2021). Correction: Effects of cancer screening restart strategies after COVID-19 disruption. British journal of cancer, 125(1), 145. https://doi.org/10.1038/s41416-021-01427-5
Kregting, Lindy M, et al. "Correction: Effects of cancer screening restart strategies after COVID-19 disruption." British journal of cancer vol. 125,1 (2021): 145. doi: https://doi.org/10.1038/s41416-021-01427-5
Kregting LM, Kaljouw S, de Jonge L, Jansen EEL, Peterse EFP, Heijnsdijk EAM, van Ravesteyn NT, Lansdorp-Vogelaar I, de Kok IMCM. Correction: Effects of cancer screening restart strategies after COVID-19 disruption. Br J Cancer. 2021 Jul;125(1):145. doi: 10.1038/s41416-021-01427-5. PMID: 33976368; PMCID: PMC8110686.
Copy Download .nbib Format: NLM
Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands.

European journal of cancer (Oxford, England : 1990)

Toes-Zoutendijk E, Vink G, Nagtegaal ID, Spaander MCW, Dekker E, van Leerdam ME, Siesling S, Lansdorp-Vogelaar I, Elferink MAG.
PMID: 34915408
Eur J Cancer. 2022 Jan;161:38-43. doi: 10.1016/j.ejca.2021.11.008. Epub 2021 Nov 24.

Many countries had to suspend their colorectal cancer (CRC) screening programme as a result of the COVID-19 pandemic. This eventually may lead to postponed diagnoses of premalignant lesions and CRC, resulting in increased incidence or more advanced CRCs rates....

Cite
Toes-Zoutendijk E, Vink G, Nagtegaal ID, et al. Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. Eur J Cancer. 2021;161:38-43doi: 10.1016/j.ejca.2021.11.008.
Toes-Zoutendijk, E., Vink, G., Nagtegaal, I. D., Spaander, M. C. W., Dekker, E., van Leerdam, M. E., Siesling, S., Lansdorp-Vogelaar, I., Elferink, M. A. G. (2022). Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. European journal of cancer (Oxford, England : 1990), 16138-43. https://doi.org/10.1016/j.ejca.2021.11.008
Toes-Zoutendijk, Esther, et al. "Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands." European journal of cancer (Oxford, England : 1990) vol. 161 (2022): 38-43. doi: https://doi.org/10.1016/j.ejca.2021.11.008
Toes-Zoutendijk E, Vink G, Nagtegaal ID, Spaander MCW, Dekker E, van Leerdam ME, Siesling S, Lansdorp-Vogelaar I, Elferink MAG. Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. Eur J Cancer. 2022 Jan;161:38-43. doi: 10.1016/j.ejca.2021.11.008. Epub 2021 Nov 24. PMID: 34915408.
Copy Download .nbib Format: NLM
Cost-effectiveness of colorectal cancer screening in Slovakia.

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)

Babela R, Orsagh A, Ricova J, Lansdorp-Vogelaar I, Csanadi M, De Koning H, Reckova M.
PMID: 34789653
Eur J Cancer Prev. 2021 Nov 16; doi: 10.1097/CEJ.0000000000000727. Epub 2021 Nov 16.

BACKGROUND: Colorectal cancer (CRC) is an ideal disease for screening due to known and detectable precursor lesions and slow progression from benign adenoma to invasive cancer. The introduction of organized population-based screening programs reduces the burden of colorectal cancer...

Cite
Babela R, Orsagh A, Ricova J, et al. Cost-effectiveness of colorectal cancer screening in Slovakia. Eur J Cancer Prev. 2021;doi: 10.1097/CEJ.0000000000000727.
Babela, R., Orsagh, A., Ricova, J., Lansdorp-Vogelaar, I., Csanadi, M., De Koning, H., & Reckova, M. (2021). Cost-effectiveness of colorectal cancer screening in Slovakia. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), . https://doi.org/10.1097/CEJ.0000000000000727
Babela, Robert, et al. "Cost-effectiveness of colorectal cancer screening in Slovakia." European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) vol. (2021). doi: https://doi.org/10.1097/CEJ.0000000000000727
Babela R, Orsagh A, Ricova J, Lansdorp-Vogelaar I, Csanadi M, De Koning H, Reckova M. Cost-effectiveness of colorectal cancer screening in Slovakia. Eur J Cancer Prev. 2021 Nov 16; doi: 10.1097/CEJ.0000000000000727. Epub 2021 Nov 16. PMID: 34789653.
Copy Download .nbib Format: NLM
Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.

Gastroenterology

Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I.
PMID: 29288655
Gastroenterology. 2017 Dec 27; doi: 10.1053/j.gastro.2017.12.011. Epub 2017 Dec 27.

BACKGROUND & AIMS: Individuals with cystic fibrosis are at increased risk of colorectal cancer (CRC) compared to the general population, and risk is higher among those who received an organ transplant. We performed a cost-effectiveness analysis to determine optimal...

Cite
Gini A, Zauber AG, Cenin DR, et al. Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gastroenterology. 2017;doi: 10.1053/j.gastro.2017.12.011.
Gini, A., Zauber, A. G., Cenin, D. R., Omidvari, A. H., Hempstead, S. E., Fink, A. K., Lowenfels, A. B., & Lansdorp-Vogelaar, I. (2017). Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gastroenterology, . https://doi.org/10.1053/j.gastro.2017.12.011
Gini, Andrea, et al. "Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer." Gastroenterology vol. (2017). doi: https://doi.org/10.1053/j.gastro.2017.12.011
Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I. Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gastroenterology. 2017 Dec 27; doi: 10.1053/j.gastro.2017.12.011. Epub 2017 Dec 27. PMID: 29288655.
Copy Download .nbib Format: NLM
The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.

Gastroenterology

Omidvari AH, Hazelton WD, Lauren BN, Naber SK, Lee M, Ali A, Seguin C, Kong CY, Richmond E, Rubenstein JH, Luebeck GE, Inadomi JM, Hur C, Lansdorp-Vogelaar I.
PMID: 33974935
Gastroenterology. 2021 Aug;161(2):487-494.e4. doi: 10.1053/j.gastro.2021.05.003. Epub 2021 May 08.

BACKGROUND AND AIMS: Current guidelines recommend surveillance for patients with nondysplastic Barrett's esophagus (NDBE) but do not include a recommended age for discontinuing surveillance. This study aimed to determine the optimal age for last surveillance of NDBE patients stratified...

Cite
Omidvari AH, Hazelton WD, Lauren BN, et al. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology. 2021;161(2):487-494.e4doi: 10.1053/j.gastro.2021.05.003.
Omidvari, A. H., Hazelton, W. D., Lauren, B. N., Naber, S. K., Lee, M., Ali, A., Seguin, C., Kong, C. Y., Richmond, E., Rubenstein, J. H., Luebeck, G. E., Inadomi, J. M., Hur, C., & Lansdorp-Vogelaar, I. (2021). The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 161(2), 487-494.e4. https://doi.org/10.1053/j.gastro.2021.05.003
Omidvari, Amir-Houshang, et al. "The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis." Gastroenterology vol. 161,2 (2021): 487-494.e4. doi: https://doi.org/10.1053/j.gastro.2021.05.003
Omidvari AH, Hazelton WD, Lauren BN, Naber SK, Lee M, Ali A, Seguin C, Kong CY, Richmond E, Rubenstein JH, Luebeck GE, Inadomi JM, Hur C, Lansdorp-Vogelaar I. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology. 2021 Aug;161(2):487-494.e4. doi: 10.1053/j.gastro.2021.05.003. Epub 2021 May 08. PMID: 33974935; PMCID: PMC8495224.
Copy Download .nbib Format: NLM
The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.

Gastroenterology

Omidvari AH, Hazelton WD, Lauren BN, Naber SK, Lee M, Ali A, Seguin C, Kong CY, Richmond E, Rubenstein JH, Luebeck GE, Inadomi JM, Hur C, Lansdorp-Vogelaar I.
PMID: 33974935
Gastroenterology. 2021 Aug;161(2):487-494.e4. doi: 10.1053/j.gastro.2021.05.003. Epub 2021 May 08.

BACKGROUND AND AIMS: Current guidelines recommend surveillance for patients with nondysplastic Barrett's esophagus (NDBE) but do not include a recommended age for discontinuing surveillance. This study aimed to determine the optimal age for last surveillance of NDBE patients stratified...

Cite
Omidvari AH, Hazelton WD, Lauren BN, et al. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology. 2021;161(2):487-494.e4doi: 10.1053/j.gastro.2021.05.003.
Omidvari, A. H., Hazelton, W. D., Lauren, B. N., Naber, S. K., Lee, M., Ali, A., Seguin, C., Kong, C. Y., Richmond, E., Rubenstein, J. H., Luebeck, G. E., Inadomi, J. M., Hur, C., & Lansdorp-Vogelaar, I. (2021). The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 161(2), 487-494.e4. https://doi.org/10.1053/j.gastro.2021.05.003
Omidvari, Amir-Houshang, et al. "The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis." Gastroenterology vol. 161,2 (2021): 487-494.e4. doi: https://doi.org/10.1053/j.gastro.2021.05.003
Omidvari AH, Hazelton WD, Lauren BN, Naber SK, Lee M, Ali A, Seguin C, Kong CY, Richmond E, Rubenstein JH, Luebeck GE, Inadomi JM, Hur C, Lansdorp-Vogelaar I. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology. 2021 Aug;161(2):487-494.e4. doi: 10.1053/j.gastro.2021.05.003. Epub 2021 May 08. PMID: 33974935; PMCID: PMC8495224.
Copy Download .nbib Format: NLM
Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors.

Journal of clinical medicine

Ykema B, Rigter L, Spaander M, Moons L, Bisseling T, Aleman B, de Boer JP, Lugtenburg P, Janus C, Petersen E, Roesink J, Raemaekers J, van der Maazen R, Lansdorp-Vogelaar I, Gini A, Verbeek W, Lemmens M, Meijer G, van Leeuwen F, Snaebjornsson P, Carvalho B, van Leerdam M.
PMID: 31936745
J Clin Med. 2020 Jan 10;9(1). doi: 10.3390/jcm9010190.

BACKGROUND: Hodgkin lymphoma (HL) survivors have an increased colorectal cancer (CRC) risk. Diagnostic accuracy of quantitative fecal immunochemical testing (FIT, OC Sensor) and/or a multi-target stool DNA test (mt-sDNA, CologuardMETHODS: 101 HL survivors underwent a surveillance colonoscopy and were...

Cite
Ykema B, Rigter L, Spaander M, et al. Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. J Clin Med. 2020;9(1)doi: 10.3390/jcm9010190.
Ykema, B., Rigter, L., Spaander, M., Moons, L., Bisseling, T., Aleman, B., de Boer, J. P., Lugtenburg, P., Janus, C., Petersen, E., Roesink, J., Raemaekers, J., van der Maazen, R., Lansdorp-Vogelaar, I., Gini, A., Verbeek, W., Lemmens, M., Meijer, G., van Leeuwen, F., Snaebjornsson, P., Carvalho, B., & van Leerdam, M. (2020). Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. Journal of clinical medicine, 9(1), . https://doi.org/10.3390/jcm9010190
Ykema, Berbel, et al. "Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors." Journal of clinical medicine vol. 9,1 (2020). doi: https://doi.org/10.3390/jcm9010190
Ykema B, Rigter L, Spaander M, Moons L, Bisseling T, Aleman B, de Boer JP, Lugtenburg P, Janus C, Petersen E, Roesink J, Raemaekers J, van der Maazen R, Lansdorp-Vogelaar I, Gini A, Verbeek W, Lemmens M, Meijer G, van Leeuwen F, Snaebjornsson P, Carvalho B, van Leerdam M. Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. J Clin Med. 2020 Jan 10;9(1). doi: 10.3390/jcm9010190. PMID: 31936745; PMCID: PMC7019558.
Copy Download .nbib Format: NLM
Comparing colorectal cancer screening outcomes in the International Cancer Screening Network (ICSN): A Consortium proposal.

Gastroenterology

Segnan N, Dekker E, Doria-Rose VP, Senore C, Rabeneck L, Lansdorp-Vogelaar I.
PMID: 34687738
Gastroenterology. 2021 Oct 20; doi: 10.1053/j.gastro.2021.10.012. Epub 2021 Oct 20.

No abstract available.

Cite
Segnan N, Dekker E, Doria-Rose VP, et al. Comparing colorectal cancer screening outcomes in the International Cancer Screening Network (ICSN): A Consortium proposal. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.012.
Segnan, N., Dekker, E., Doria-Rose, V. P., Senore, C., Rabeneck, L., Lansdorp-Vogelaar, I. (2021). Comparing colorectal cancer screening outcomes in the International Cancer Screening Network (ICSN): A Consortium proposal. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.012
Segnan, N, et al. "Comparing colorectal cancer screening outcomes in the International Cancer Screening Network (ICSN): A Consortium proposal." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.012
Segnan N, Dekker E, Doria-Rose VP, Senore C, Rabeneck L, Lansdorp-Vogelaar I. Comparing colorectal cancer screening outcomes in the International Cancer Screening Network (ICSN): A Consortium proposal. Gastroenterology. 2021 Oct 20; doi: 10.1053/j.gastro.2021.10.012. Epub 2021 Oct 20. PMID: 34687738.
Copy Download .nbib Format: NLM
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.

The lancet. Gastroenterology & hepatology

Breekveldt ECH, Lansdorp-Vogelaar I, Toes-Zoutendijk E, Spaander MCW, van Vuuren AJ, van Kemenade FJ, Ramakers CRB, Dekker E, Nagtegaal ID, Krul MF, Kok NFM, Kuhlmann KFD, Vink GR, van Leerdam ME, Elferink MAG.
PMID: 34822762
Lancet Gastroenterol Hepatol. 2022 Jan;7(1):60-68. doi: 10.1016/S2468-1253(21)00368-X. Epub 2021 Nov 22.

BACKGROUND: In 2014, a population-based colorectal cancer (CRC) screening programme was stepwise implemented in the Netherlands comprising faecal immunochemical testing once every 2 years, with a cutoff value for positivity of 47 μg haemoglobin per g faeces. We aimed...

Cite
Breekveldt ECH, Lansdorp-Vogelaar I, Toes-Zoutendijk E, et al. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. Lancet Gastroenterol Hepatol. 2021;7(1):60-68doi: 10.1016/S2468-1253(21)00368-X.
Breekveldt, E. C. H., Lansdorp-Vogelaar, I., Toes-Zoutendijk, E., Spaander, M. C. W., van Vuuren, A. J., van Kemenade, F. J., Ramakers, C. R. B., Dekker, E., Nagtegaal, I. D., Krul, M. F., Kok, N. F. M., Kuhlmann, K. F. D., Vink, G. R., van Leerdam, M. E., Elferink, M. A. G. (2022). Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. The lancet. Gastroenterology & hepatology, 7(1), 60-68. https://doi.org/10.1016/S2468-1253(21)00368-X
Breekveldt, Emilie C H, et al. "Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study." The lancet. Gastroenterology & hepatology vol. 7,1 (2022): 60-68. doi: https://doi.org/10.1016/S2468-1253(21)00368-X
Breekveldt ECH, Lansdorp-Vogelaar I, Toes-Zoutendijk E, Spaander MCW, van Vuuren AJ, van Kemenade FJ, Ramakers CRB, Dekker E, Nagtegaal ID, Krul MF, Kok NFM, Kuhlmann KFD, Vink GR, van Leerdam ME, Elferink MAG. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):60-68. doi: 10.1016/S2468-1253(21)00368-X. Epub 2021 Nov 22. PMID: 34822762.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 37 entries